AF Ablation Devices Need Randomized Trials, Advisory Panel Tells FDA

An FDA advisory panel is encouraging the agency to continue requiring randomized controlled trials of atrial fibrillation ablation devices while allowing sponsors to relax the trials' inclusion criteria